Abstract
Recently, microarray technology is reshaping the molecular biology, given the high number of fields of application like, gene expression analysis, rapid sequencing of DNA, mapping of allelic variation, identification polymorphisms. It is a recently developed technique, which allows analysing thousands of genes in a very short time. Due to the powerful nature of this genetic approach, the number of researches using microarray technology boosted in the last years (less than ten papers from 1995 to 1997, up to approximately one thousand in the following 5 years -PubMed). Nevertheless, in spite of the promising fields of application, many drawbacks need to be carefully considered before generalizing the results obtained with this new technology. In fact, up to now a number of drawbacks have been described in the use of DNA microarray: many errors of incorporation during the manufacturing of the chips, loss of splicing variants, variable reliability of differential expression data, low specificity of cDNA microarray probes, discrepancy in fold change calculation for a given gene and so on. In spite of all those troubles, there is no doubt that this new promising technology could give an overall idea of gene organization and expression and might contribute to understanding the molecular mechanisms involved in processes as disease diagnosis or drug discovery (Pharmacogenetics and Pharmacogenomics). The goal of the present review is to suggest a targeted use of DNA chip technology in the field of pharmacogenetics (with the example of antidepressants), suggesting the inclusion of only those genes, possibly candidates, through a step by step analysis of the pathways involved in the pharmacological action of antidepressants.
Keywords: pharmacogenetics, microarray, chips, review
Current Genomics
Title: The Use of DNA Microarray in the Pharmacogenetics of Antidepressants: Guidelines for a Targeted Approach
Volume: 5 Issue: 6
Author(s): Cristina Lorenzi, Viviana Tubazio, Alessandro Serretti and Diana De Ronchi
Affiliation:
Keywords: pharmacogenetics, microarray, chips, review
Abstract: Recently, microarray technology is reshaping the molecular biology, given the high number of fields of application like, gene expression analysis, rapid sequencing of DNA, mapping of allelic variation, identification polymorphisms. It is a recently developed technique, which allows analysing thousands of genes in a very short time. Due to the powerful nature of this genetic approach, the number of researches using microarray technology boosted in the last years (less than ten papers from 1995 to 1997, up to approximately one thousand in the following 5 years -PubMed). Nevertheless, in spite of the promising fields of application, many drawbacks need to be carefully considered before generalizing the results obtained with this new technology. In fact, up to now a number of drawbacks have been described in the use of DNA microarray: many errors of incorporation during the manufacturing of the chips, loss of splicing variants, variable reliability of differential expression data, low specificity of cDNA microarray probes, discrepancy in fold change calculation for a given gene and so on. In spite of all those troubles, there is no doubt that this new promising technology could give an overall idea of gene organization and expression and might contribute to understanding the molecular mechanisms involved in processes as disease diagnosis or drug discovery (Pharmacogenetics and Pharmacogenomics). The goal of the present review is to suggest a targeted use of DNA chip technology in the field of pharmacogenetics (with the example of antidepressants), suggesting the inclusion of only those genes, possibly candidates, through a step by step analysis of the pathways involved in the pharmacological action of antidepressants.
Export Options
About this article
Cite this article as:
Lorenzi Cristina, Tubazio Viviana, Serretti Alessandro and Ronchi De Diana, The Use of DNA Microarray in the Pharmacogenetics of Antidepressants: Guidelines for a Targeted Approach, Current Genomics 2004; 5 (6) . https://dx.doi.org/10.2174/1389202043348913
DOI https://dx.doi.org/10.2174/1389202043348913 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
TNF-α and Ghrelin: Opposite Effects on Immune System, Metabolism and Mental Health
Protein & Peptide Letters HPA Axis Function During the Perinatal Period in Patients with Affective Disorders
Current Psychiatry Reviews Multifunctional Proteins in Tumorigenesis: Aminoacyl-tRNA Synthetases and Translational Components
Current Proteomics Characterization of Hypersecreting or Non-Hypersecreting Adrenal Adenomas: Comparison between Iodine-131 Nor-Cholesterol Scintigraphy and Magnetic Resonance Imaging
Current Radiopharmaceuticals Current Challenges to Overcome in the Management of Type 2 Diabetes Mellitus and Associated Neurological Disorders
CNS & Neurological Disorders - Drug Targets ABC Subfamily D Proteins and Very Long Chain Fatty Acid Metabolism as Novel Targets in Adrenoleukodystrophy
Current Drug Targets Lifelong Endocrine Fluctuations and Related Cognitive Disorders
Current Pharmaceutical Design “Letting the Air In” Can Set the Stage for Tumor Recurrences
Current Cancer Therapy Reviews Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer
Current Medicinal Chemistry Reconceptualizing Adult Neurogenesis: Role for Sphingosine-1-Phosphate and Fibroblast Growth Factor-1 in Co-Ordinating Astrocyte-Neuronal Precursor Interactions
CNS & Neurological Disorders - Drug Targets Subject Index To Volume 6
Current Molecular Medicine Suramin: Clinical Uses and Structure-Activity Relationships
Mini-Reviews in Medicinal Chemistry Genitourinary Tract Tumors in Children: An Update
Current Pediatric Reviews Polycystic Ovary Syndrome in Adolescents
Current Women`s Health Reviews Prospects for Anti-Neoplastic Therapies Based on Telomere Biology
Current Cancer Drug Targets Nicotine, Body Weight and Potential Implications in the Treatment of Obesity
Current Topics in Medicinal Chemistry Linear Naphtho-γ-Pyrones: A Naturally Occurring Scaffold of Biological Importance
Mini-Reviews in Medicinal Chemistry Epigenetic Regulation of ABCB1 Transporter Expression and Function
Current Pharmacogenomics and Personalized Medicine Diagnosis and Management of Endocrine Hypertension in Children and Adolescents
Current Pharmaceutical Design Pituitary Adenylate Cyclase Activating Polypeptide: A Potential Neuroprotective Peptide
Current Pharmaceutical Design